Traws Pharma (TRAW) CSO receives new RSUs and stock options grant

Rhea-AI Filing Summary

Traws Pharma, Inc. reported that its Chief Science Officer for Virology received new equity awards on December 12, 2025. The filing shows an acquisition of 18,471 shares of common stock, described as restricted stock units that will vest 100% on the first anniversary of the grant date, with each unit converting into one share of common stock. Following this grant, the officer beneficially owns 115,971 shares of common stock.

The officer was also granted a stock option for 73,886 shares of common stock at an exercise price of $2.33 per share. These options vest 100% on the first anniversary of the grant date, becoming exercisable on December 12, 2026, and expire on December 12, 2035. Both the common stock and the options are held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pauza Charles David

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Science Officer Virology

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		A		18,471(1)	A	$0	115,971	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to purchase)	$2.33	12/12/2025		A		73,886		12/12/2026(2)	12/12/2035	Common Stock	73,886	$0	73,886	D

Explanation of Responses:

1. Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

2. The options vest 100% on the first anniversary of the grant date.

	/s/ Charles David Pauza	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Traws Pharma (TRAW) report in this Form 4?

The report shows Traws Pharma's Chief Science Officer for Virology received 18,471 shares of common stock as a restricted stock unit award and a stock option covering 73,886 shares of common stock on December 12, 2025.

How many Traws Pharma (TRAW) shares does the officer own after this transaction?

After the reported grant of restricted stock units, the officer beneficially owns 115,971 shares of Traws Pharma common stock, held directly.

What are the vesting terms of the restricted stock units granted by Traws Pharma (TRAW)?

The 18,471 restricted stock units will vest 100% on the first anniversary of the grant date, and each unit will convert into one share of Traws Pharma common stock.

What are the key terms of the stock options granted by Traws Pharma (TRAW)?

The officer received a stock option for 73,886 shares of common stock at an exercise price of $2.33 per share. The options vest 100% on the first anniversary of the grant date, become exercisable on December 12, 2026, and expire on December 12, 2035.

What role does the reporting person hold at Traws Pharma (TRAW)?

The reporting person is an officer of Traws Pharma, serving as the Chief Science Officer Virology.

Are the reported Traws Pharma (TRAW) equity awards held directly or indirectly?

Both the common stock and the stock options reported in this filing are held in direct ownership by the officer.